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Calciphylaxis or calciﬁc uremic arteriolopathy is an infrequent complication of end stage kidney disease. It is characterized by
arteriolar medial calciﬁcation, thrombotic cutaneous ischemia, tissue necrosis often leading to ulceration, secondary infection and
increased mortality rates. Current, multimodality treatment involves local wound care, well-controlled calcium, phosphate and
parathyroid hormone levels and combination therapy with sodium thiosulfate and hyperbaric oxygen therapy. This combination
therapy may be changing the historically poor prognosis of calciﬁc uremic arteriolopathy reported in the literature. Peritoneal
dialysis is considered a risk factor based on limited publications, however this remains to be proven. Clinical presentation,
diagnosis, pathogenesis and treatment of calciﬁc uremic arteriolopathy in these patients are no diﬀerent from other patients
manifesting with this condition.
1.Introduction
Calciﬁc uremic arteriolopathy (CUA), commonly referred to
ascalciphylaxis,isanuncommonbutincreasinglyrecognized
disorder associated with high morbidity and mortality.
Althoughthedisorderwasﬁrstreportedin1898[1],theterm
calciphylaxis was coined by Selye in 1962 as a condition of
systemic hypersensitivity induced by a sensitizing agent that
resulted in metastatic calciﬁcation in various organs analo-
gous to anaphylaxis [2].
It is characterized by tender plaques or nodules with vio-
laceousdiscolorationassociatedwithseverepainthatisoften
refractory to standard analgesia [3]. Historically, CUA has
been associated with signiﬁcant morbidity including debil-
itating pain, surgical resections, and amputations. More
than 50% die within one year of diagnosis, usually due to
superimposed sepsis [4]. Approximately 1–4% patients with
chronic kidney disease (CKD) manifest CUA, and a recent
report estimates a prevalence of 4% in patients with end-
stage kidney disease (ESKD) [5]. The pathogenesis of CUA is
poorly understood; however, many putative risk factors such
as female gender, hyperphosphatemia, hypercalcemia, high
calcium phosphorous product [6], use of calcium containing
phosphate binders, and hypercoagulable states are reported
[6,7].NonuremicCUAisalsoreported,mostlyinthecontext
of primary hyperparathyroidism, malignancy, alcoholic liver
disease, or connective tissue diseases [8]. Mineral abnormal-
ities that are postulated in CUA are often absent in these
patients suggesting that various factors play a role in its path-
ogenesis. Peritoneal dialysis (PD) is shown to be a risk factor
for CUA in one prospective cohort [9]b u th a sn o tb e e ns u b -
sequently substantiated adequately. Further, the exact mech-
anism of presumed increased incidence of CUA in PD
patients is not well described and in one report was attrib-
utedtotheuseofcalciumcontainingphosphatebinders[10].
The introduction of early aggressive therapy with sodium
thiosulfate (STS) and hyperbaric oxygen therapy (HBO), in
addition to local wound care, calcium, phosphate, and par-
athyroid hormone (PTH) control, is hoped to improve the2 International Journal of Nephrology
Figure 1: CUA lesion on the lateral abdominal wall with early
ulceration, surrounding erythema and induration.
Figure 2: Large CUA lesion of the proximal lower limb with
necrotic ulceration.
very poor outcome of this debilitating condition. The aim of
this paper is to study the clinical features, pathogenesis and
management of CUA in PD patients.
2. ClinicalPresentation
CUA is now a well-described entity in the nephrology litera-
tureinbothhemodialysis(HD)andPDpatients.Aspectrum
ofdiseasehasbeendescribed(Table1),mostlikelyrepresent-
ing a continuum dependent on both the underlying severity
and the duration of disease.
Early lesions present with localized erythema, skin indu-
ration, and associated pain and tenderness, as documented
in the cases identiﬁed by Fine and Zacharias [10]. Untreated,
theselesions tendtoprogresstobecomepainfulplaqueswith
violaceous discoloration and formation of a central eschar.
Progression leads to central ulceration (Figure 1)w i t ha n
expanding border of necrosis (Figure 2) invariably associated
withintensepainrequiring,andoftenresistantto,highdoses
of opioids. Severity of disease has been proposed to correlate
with high mortality rate and likely treatment failure.
The distribution of the lesions predominantly involves
the lower limbs and the abdomen. Upper extremity [13, 14],
breast [13], penis, vulva [16], and cardiac and pulmonary
[17] involvement have also been documented. Some authors
suggest a distal distribution, in comparison with more prox-
imal, portends a better prognosis [16]. However, this has not
been proven.
Radiological investigations support but not conﬁrm the
diagnosis. Plain radiographic ﬁlms of involved soft tissue
maydemonstrateareasofcalciﬁcationrepresentativeofsmall
vessel calciﬁcation. Standard mammography technique of
involved soft tissue increases the sensitivity of imaging and is
more sensitive than high-resolution-computed tomography
[18]. The characteristic mesh-like pattern of arterioles dem-
onstrated in CUA using a mammographic technique was not
present in a long-term HD patient when CUA was absent
[18].
Histological diagnosis remains the gold standard al-
though it is often avoided for fear of poor wound healing
and exacerbating associated ulceration [9]. Histopathologic
features are small and medium vessel involvement with cir-
cumferential wall calciﬁcation involving both the medial and
intimal layers. There may be associated intimal hyperplasia
withpartialobliterationofthevessellumen.Acuteorchronic
panniculitis with a relative absence of inﬂammatory cells is
a frequent feature [16]. Fibrin thrombi are often noted and
are in close proximity to epidermal and dermal necrosis.
Necrosis can extend into the subcutaneous tissue.
3.A Local Cohort of PeritonealDialysis
Patients withCUA
A retrospective chart analysis from 2007 to 2010 identiﬁed
5 PD patients treated for CUA within our centre (Table 2).
This represents an annual incidence of 0.97%, with one
patient excluded due to referral from outside our local
treatment population. An additional 4 HD patients in our
centre were identiﬁed, not included here, with an annual
incidence of 0.75%. Patient characteristics were similar to
those documented in the literature (Table 1). Three of ﬁve
were male, all with hypertension and two with ischemic
heart disease. Only one had diabetes and none treated
with therapeutic anticoagulation with either heparin or
warfarin.Hyperphosphatemiawasuniversal,whiletwoofthe
ﬁve also had hypercalcemia at presentation. Time-averaged
phosphate and calcium levels were not available. The average
calcium-phosphate product was 5.46mmol2/L2.T h e r ew a sa
widerangeinparathyroidhormonelevels(PTH).Ofnoteisa
28-years old female with ESKD secondary to lupus nephritis
with suppressed PTH and intact parathyroid glands. Similar
presentations have been noted previously with underlying
SLE and normal or suppressed PTH [19, 20].
All our patients presented with ulcerative lesions. The
margins of ulceration were biopsied and examined by
a pathologist who was blinded to clinical severity (Figure 3.)
There was no association between the size of involved
vessel, maximal degree of luminal narrowing, associated
changesincluding:ulceration,epidermalnecrosis,panniculi-
tis, fat necrosis, thrombosis, calciﬁcation (septal, lobular,
or both), and outcome. Despite patients presenting with
ulcerative lesions, outcomes were better than expected from
the literature. We suggest the better outcomes are due to
a multimodality approach with STS and HBO.International Journal of Nephrology 3
Table 1: CUA cases in PD population described within the literature.
Patient numbers,
patient
characteristics
PD duration Clinical
presentation
CCa2+
(mmol/L)
PO
−
4
(mmol/L)
PTH
(ng/L) Treatment Outcome Reference
n = 54 most
female diabetics > 2m o n t h s
73% subcutaneous
plaques 95% lower
legs (95% bilateral)
5% abdomina l
wall
n/a n/a n/a
Parathyroidectomy
(n = 6) 5i m p r o v e
Change to HD
(n = 13) 11 improve [11]
Steroid therapy
(n = 19)
3 die within 3
month8
improve 8 no
change
n = 169
female HTN, IHD,
renal calculi,
osteoarthritis,
graves thyroid
disease,
osteoporosis
3m o n t h s
Unilateral right calf
violaceous lesion
1.5 inch,
progressing to
bilateral indurated
lesions calf and
thighs
2.22 2.10 109
D/C caltrate,
calcitriol start
sevelamer
prednisolone STS
(IV)
Resistant to all
but STS, with
improved pain
in 2 weeks, and
reduced lesion
size in 8 weeks
[12]
n = 126
female 2 failed
transplant not on
calcium salts
4 years
Violaceous lesions
progressing in 6
weeks to
ulcerations of left
proximal arm and
bilateral thigh
2.4 1.77 89
Prior parathy-
roidectomy,
initially STS (IV) 2
months STS (IP) 4
months
STS(IV)
response but
D/C due to
N&V. STS(IP)
no response and
died from sepsis
[13]
n = 153
female Moroccan
obese, IDDM,
IHD, CVA
3 years
Redness right
breast progressed
to ulcerate Further
progressed to
bilateral breast and
ﬁngertip
ulceration. Further
progression to
thigh
2.7 2.0 1376
Parathyroidectomy
mastectomy
STS—although
very late
Poor response
to all. Poor
wound healing.
Died from sepsis
[14]
n = 117
male
Afro-American
Wegener’s
granulomatosis
(receiving
cyclophosphamide
and prednisolone)
previous warfarin
(right atrial
thrombus)
3 years
Erythema and
swelling bilateral
metatarsals,
progressed to
necrotic feet and
ﬁngers, with
scintigraphy
evidence of
widespread disease
2.42 2.68 321
D/C caltrate
Sevelamer
preexisting
Aluminium
commenced STS
(IV) 3 months
HBO Change to
HD
Pain relief with
STS but lesions
progress. HBO
did not halt
Proceed to
bilateral BKA.
Change to HD
5x/week and
disease healed
[15]
PD: peritoneal dialysis, CCa2+: corrected calcium, PO4
−:p h o s p h a t e ,P T H :p a r a t h y r o i dh o r m o n e ,n: number, HD: hemodialysis, HTN: hypertension, IHD:
ischemic heart disease, D/C: discontinue, STS: sodium thiosulphate, IV: intravenous, IP: intraperitoneal, N&V:, nausea and vomiting, IDDM: insulin-
dependent diabetes mellitus, CVA: cerebrovascular accident, HBO: hyperbaric oxygen therapy, and BKA: below knee amputation.
4. Risk Factors
Although many authors have proposed potential risk factors
in CUA, its low frequency has restricted analysis design to
retrospective case control studies with only one prospective
study reported in the PD population [11]. Females are
disproportionately represented with Zacharias documenting
75% of cases being female, compared with 53% females in
the background PD population [10]. Female predominance
has also been observed in HD populations [7]. Diabetes is
another potential risk factor in patients with a frequency of
67% in CUA, compared to 29% in PD patients without CUA
[9]. This association is not conﬁrmed in the HD population
[7].
Fine reported a link between PD and increased risk of
CUA with a reported incidence of approximately 4% during4 International Journal of Nephrology
Figure 3: Characteristic biopsy specimen of CUA demonstrating
circumferential calciﬁcation of small blood vessels with narrowing
of the vascular lumen.
the late 1990s, but with a declining incidence during the
last decade [9]. However, the literature reports a similar
incidence of 4.1% within a HD population [21]. Single-
centre studies report the proportion of PD suﬀering CUA
to be higher than the HD population [9]. Supporting the
notion of dialysis modality being a contributing factor is the
reported therapeutic response in CUA with a change from
PD to HD. Reasons for this remain unclear although the
constant high levels of phosphate in PD, in comparison with
t h eﬂ u c t u a t i o n ss e e ni nH D ,m a yc o n t r i b u t e .
Use of calcium containing phosphate binders during the
months preceding CUA onset was suggested to contribute
to the incidence in PD patients [10] with the observation
of decreasing incidence following the introduction of non-
calcium containing phosphate binders [9]. It must be noted
that these observations were not controlled for hyperphos-
phatemia. Hyperphosphatemia was identiﬁed as the only
signiﬁcant risk factor in a HD population although the small
sample size of nineteen limited the power of this study [7].
Retrospective case-controlled cohort analyses have iden-
tiﬁed numerous other potential risk factors, including time
on dialysis [7], obesity [22], and warfarin use [23], in the
development of CUA.
5. Pathogenesis
The molecular biology of intimal and medial vascular cal-
ciﬁcation is a subject currently attracting considerable inter-
est in the literature and is particularly pertinent to the ESKD
population where widespread large vessel, that is, arterial,
calciﬁcation is common [24]. Small and medium arteriolar
vessel calciﬁcation, as seen in CUA, is much less common.
In the absence of data in CUA, the molecular biology is
presumed to be similar [3, 24]. Identifying the stimulus for
thedevelopmentofCUA,andhowitselectspatients,remains
elusive. However, it is unlikely to be a single injury but rather
the sum of a variable combination of multiple processes.
Pathophysiological mechanisms of established CUA remain
largely theoretical. The emergence of possible treatment
modalities has sparked interest in research into identiﬁ-
cation of these mechanisms. Hans Selye [2] hypothesized
a “two-hit” mechanism for CUA in a rat model, whereby
sensitization with either vitamin D or intact endogenous
parathyroid hormone would prime the animal for the
development of “calciphylaxis” when injected with either
iron preparation or egg white compound.
Disordered mineral metabolism of the calcium, phos-
phate, and parathyroid axis is almost universally assumed
t op l a yar o l ei nC U A .A na s s o c i a t i o nb e t w e e no s t e o p o r o s i s
or osteopenia and vascular calciﬁcation has been well doc-
umented [24], although this is restricted to large vessel
calciﬁcation.Availableliteraturedoesnotconﬁrmacausative
relationship between disordered mineral metabolism and
CUA, possibly due to heterogeneity and lack of well powered
prospective studies.
Hyperphosphatemia induced vascular smooth muscle
cell (vSMC) mineralization and transition from contractile
smooth muscle to an osteochondrogenic phenotype express-
ing osteopontin, Cbfa-1/Runx2, alkaline phosphatase, and
osteocalcin in in vitro studies (Figure 4)[ 24]. Similar expres-
sion markers have been identiﬁed in human CUA biopsy
samples [25]. Long-term exposure to hypercalcemia at levels
similar to that seen in ESKD-induced mineralization of
cultured human smooth muscle cells [26]. Hypercalcemia
induced increased expression of the type III sodium depen-
dent phosphate cotransporter, Pit-1 [26]. In the presence of
both hyperphosphatemia and hypercalcemia mineralization
was dramatically enhanced.
The ﬁnal common pathway of the varying mechanisms is
the expression of nuclear factor κ-B (NFκB), a nuclear tran-
scription factor, through the complex interaction of receptor
activator of NFκB (RANK), its ligand (RANKL) and antag-
onist to the ligand, osteoprotegerin (OPG) [27]. Increased
expression of NFκB promotes extraosseous mineraliza-
tion and decreases osseous mineralization. OPG under-
expression results in osteoporosis and vascular calciﬁcation,
while increased expression results in an osteopetrosis phe-
notype [27]. The therapeutic mechanism of bisphosphonate
therapy in CUA may be explained by its inhibition of the
RANK/RANKL interaction [27]. This pathogenic mecha-
nism does not, however, explain the higher incidence in
the female and obese populations, where oestrogen, in the
former, and leptin, in the later, increase OPG levels resulting
in an expected protective eﬀect.
Otherproteinshavebeenimplicatedinvascularcalciﬁca-
tion in the ESKD population. Fetuin-A or alpha-Heremans-
Schmid glycoprotein (ASHG) has been demonstrated to
inhibit ectopic calciﬁcation in knockout mice [28]. ASHG
levelshavebeendemonstratedtobelowwithinbothHD[29]
and PD populations. Interestingly, low ASHG levels were
also shown to be a predictor of mortality and cardiovascular
death [28]. A second protein, matrix Gla protein (MGP) has
been shown to regulate medial calciﬁcation, which devel-
ops spontaneously in knock-out mice [30]. MGP requires
vitamin K as an activating cofactor, thereby providing
a mechanism of involvement for warfarin, by depleting
vitamin K. Supporting the role of these two proteins is the
observation of low MGP and ASHG levels in a HD popula-
tion, with a negative correlation to time-averaged phosphate
levels [31].International Journal of Nephrology 5
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Figure 4: Schematic representation for the pathogenic mechanisms of CUA development and the potential sites of action for therapeutic
intervention, where (+) indicates augmentation and (−) indicated inhibition; STS, sodium thiosulfate; HBO, hyperbaric oxygen; PO4
−,
phosphate; Ca++, calcium; NDPT, sodium-dependent phosphate cotransporter (Pit-1); vSMC, vascular smooth muscle cell; Cbfa-1, core-
binding factor alpha 1; NFκB, nuclear factor κ−B; RANK(L), receptor activator of NFκB (ligand); OPG, osteoprotegerin; TNF-α,tumour
necrosis factor alpha; IL-1 interleukin 1; BMP, bone morphogenic protein; ESKD, end-stage kidney disease; MGP, matrix G1a protein;
ASHG, α-2 Heremans-Schmid glycoprotein.
Iron deposition may also be involved in the development
of CUA. Farah identiﬁed iron deposition in all the analyzed
biopsyspecimensoftheirseriesofCUA[32].Elevenhadiron
deposited within the aﬀected vessel wall and iron around
the vessel wall only in the twelfth [32]. No iron deposits in
areas unaﬀected by CUA were seen in any biopsies. Whether
iron deposition is a cause, a consequence, or an unrelated
association remains to be determined. Calciﬁc narrowing of
small and medium vessels provides the milieu for additional
processes that may ultimately culminate in the development
of CUA [27]. Associated thrombosis can develop secondary
to low blood ﬂow rates through narrowed arteriolar lumens
[27].Ahmedproposesasecondmechanism,wherebyvSMCs
sloughed into the lumen aggregate to form thrombus [33].
Local small and medium vessel luminal thrombus in
addition to vessel lumen narrowing, promotes ischemia
and secondary necrosis. Systemic procoagulant states may
alsoincreasetheriskofCUAdevelopmentthroughenhanced
thrombus development.
Local and systemic inﬂammatory mediators are thought
to potentiate the development of CUA. Chronic dialysis and
diabetes are known to be associated with increased levels of
proinﬂammatory mediators, such as tumor necrosis factor
alpha, Interleukin-1 and Interleukin-6 which can result
in endothelial disruption promoting local thrombosis and
necrosis in addition to potentiation of NFκB stimulating
further vessel calciﬁcation [3, 27]. Such mechanisms may
explain the possible increased risk of CUA in diabetic pop-
ulations and with local minor trauma such as with insulin
and erythropoietin injections.
6. Treatment of CUA
6.1. General Measures
6.1.1. Local Wound Care. T h e r ei ss o m ee v i d e n c et os u p p o r t
surgical debridement of the wounds [27, 34]. The opposing
point of view is that debridement can increase the extent of6 International Journal of Nephrology
Table 2: CUA cases within our local PD population.
Patient
characteristics PD duration Clinical
presentation
CCa2+
(mmol/L)
PO4
−
(mmol/L)
PTH
(ng/L) Treatment Response to
treatment
79 yo female ESRD
(? cause) HTN, IHD,
PVD, dyslipidemia,
depression
9 years CAPD Painful bilateral
foot ulceration 2.64 2.16 598
D/C calcium
carbonate and
calcitriol Started
cinacalcet and
aluminium OHSTS
(IV) 3
monthsIntensive
PD—change to HD
With STS and
change to HD
lesions resolvedDied
7/12 after resolution
of lesions.
Withdrawal of HD
for functional
decline
67 yo male ESKD
(FSGS) IHD, HTN,
dyslipidemia, OSA,
BPH, GORD
7m o n t h sC A P D
Painful red
violaceous
ulceration right
calf: Multiple
indurated lesions
on thighs and
bilateral calf
2.42 2.61 1386
Started cinacalcet.
Parathyroidectomy
and STS (IV) 6
months commenced
at same time.
Caltrate and
calcitriol not
stopped due to
hungry bone
Complete resolution
of lesions including
ulceration. Died 18
months later with
ischemic CCF not
for intervention
75 yo male ESKD
(DM/ obstructive)
DM, IHD,
dyslipidemia, CVA,
GORD, HTN, gout
7m o n t h sC A P D
Ulcerations right
anterior lower
leg, initially
presumed DM
ulcers
2.73 1.73 132
D/C calcium
carbonate. Started
sevelamer,
cinacalcet,
aluminium OHHBO
+ pamidronate +
Intensive PD STS
(IV) 5 weeksPD
changed to HD
while on STS
No response to
change in phosphate
binders. Pain relief
gained while on STS
but no wound
healing. Ulcers
began to heal oﬀ
STS after HD
initiated. Died
secondary to sepsis
74 yo male ESKD
(ADPKD) PVD,
HTN, gout,
ex-smoker
3 years CAPD
Painful ulceration
of left shin,
superimposed
infection
2.45 2.28 38
Prior
Parathyroidectomy.
STS (IP) 12 weeks +
HBO for 5 days. PD
changed to HD after
2nd PD peritonitis
Complete response
was documented.
STS complicated by
2 episodes PD
peritonitis and was
D/C
28 yo female ESKD
(SLE) AIHA,
Epilepsy, HTN
27 months CAPD
4 painful
ulcerating lesions
left lower leg
medial and
posterior
2.42 1.90 8.54
Started sevelamer.
STS (IP) 3 months
−25g was reduced
to 12.5g for nausea.
HBO 30 treatments
Complete response,
with durability to 2
years. Remaining on
PD
PD peritoneal dialysis, CCa2+ c o r r e c t e dc a l c i u m ,P O 4
− phosphate, PTH parathyroid hormone, ESRD (aetiology), HD haemodialysis, HTN hypertension,
IHD ischemic heart disease, PVD peripheral vascular disease, CAPD continuous abdominal PD, D/C discontinue, STS sodium thiosulphate, IV intravenous,
IP intraperitoneal, OSA obstructive sleep apnoea, AIHA autoimmune hemolytic anemia, DM diabetes mellitus, CVA cerebrovascular accident, and HBO
hyperbaric oxygen therapy.
the nonhealing ulcer surface. The use of antibiotics is limited
to obvious bacterial infection rather than colonization.
6.1.2. Nutrition. CUA is most often painful and associated
with depression which both impact the nutritional state.
Necrotic tissues reduce appetite, possibly through the release
of cytokines. Adequate analgesia with nonsteroidal anti-
inﬂammatory drugs and opioids without signiﬁcantly aﬀect-
ing quality of life is important, as is supportive psychother-
apy.
6.1.3. Cessation of Warfarin. Warfarin inhibits matrix GLA
metalloproteinases, thus promoting vascular calciﬁcation.
Based on this molecular mechanism, stopping warfarin with
vitamin K reversal has become a common practice despite
scant clinical evidence [23]. Substitution with low molecular
weight heparin (LMWH) is a reasonable long-term manage-
ment strategy, where anticoagulation is mandated. Thera-
peutic bridging from warfarin to LMWH with monitoring
of Factor Xa levels is performed in those with mandated
therapeutic anticoagulation. Conditions such as atrial ﬁb-
rillation necessitate and individualized decision, recognizing
traditional risk beneﬁt ratios demonstrated in the general
public cannot be generalized to the dialysis population [35].
Management is determined by the balance of risk of stroke
or thrombosis, ability to administer and monitor LMWH,International Journal of Nephrology 7
patient preferences and risk of LMWH, including the cu-
mulative risk of precipitating new CUA lesions through
endothelial damage from subcutaneous injections [3].
6.2. Vitamin K Administration. Regular administration of
Vitamin K has not been investigated. Through the γ–
carboxylation of MGP, Vitamin K administration may have
a therapeutic beneﬁt [36] although likely small.
6.3. Lowering the Calcium Phosphorus Product
6.3.1. Substitution with Non-Calcium Containing Phosphate
Binders Like Sevelamer and Lanthanum Carbonate May Be
Beneﬁcial [27, 37]. Change of dialysis prescription to: inten-
siﬁedPD,extendedhoursofHDordailyHDhasbeenshown
to be beneﬁcial in some patients [38]. Changing to HD from
PD has been trialed in the past with dramatic improvement
in some patients and not in others [11].
6.3.2. Reduction of Elevated PTH Levels. The relationship of
CUAwithhyperparathyroidismisbestseeninthenonuremic
population [8]. There are also reports of ulcer healing,
pain relief and survival beneﬁt in patients on dialysis with
CUA and hyperparathyroidism who undergo parathyroidec-
tomy [39]. Medical treatment of hyperparathyroidism with
cinacalcet, a relatively recent option, was reported to be ben-
eﬁcial [40]. Our local practice is surgical parathyroidectomy
in the presence of uncontrolled hyperparathyroidism, that is,
hormone levels greater than seven to nine times the upper
limit of reference range (CARI guidelines [41]). Cinacalcet is
used in those who are not surgical candidates.
6.4. Emerging Treatment Options
6.4.1.SodiumThiosulfate(STS). STSactsasachelatingagent
for calcium and iron and also as a potent antioxidant result-
ing in decreased vasospasm and pain along with solubiliza-
tion and decalciﬁcation of the deposits [42, 43]. STS can be
givenorally[40],intravenously(IV)[12]orintraperitoneally
(IP) [13]. There is no consensus on the best dosing schedule
and STS is given at varying regimes, including 7.5g/week
orally [40], 12.5g [44] to 25g IV or IP three times a week.
Intravenous STS can cause abdominal cramping, nausea,
vomiting, and diarrhea if infused rapidly [45]. Acidosis and
hypocalcemia have been reported [46]. We used STS in all
our PD patients with CUA. In three patients, we admin-
i s t e r e dS T SI Va n dc o n v e r t e dt h e mt oH D .H o w e v e rw e
left the last two patients on PD and administered 12.5g
of STS in 2 litres of the long dwell dialysate, three times
a week. One patient developed bacterial peritonitis after
one week of therapy, which was treated according to the
International Society of Peritonitis Dialysis guidelines and
continued onIP STS and PD. Twomonths later,he presented
again with culture negative peritonitis raising the possibility
of chemical peritonitis. He also developed tremors and we
stopped IP STS due to concern over STS causing these side
eﬀects. The second patient received STS IP for 3 months
uneventfullyandtherewasacompletehealingofskinlesions.
The optimum dose and duration of treatment with STS is yet
to be determined.
6.4.2. Hyperbaric Oxygenation Therapy (HBO). This modal-
ity is increasingly used for its beneﬁts of better tissue oxy-
genation, improved angiogenesis, and enhanced phagocytic
activity and bactericidal action in tissues with CUA and
hypoxemia driven injury [47]. Ulcers heal in 40% to 75%
of treated patients [48, 49]. Reported side eﬀects are baro-
trauma, reversible myopia and neurological complications
from oxygen toxicity [50]. Logistical constraints may limit its
use as HBO may not be available in all centers, necessitating
transfer of patients to a unit with such facilities.
6.4.3. Combination Therapy. Aggressive therapy with a com-
bination of all these modalities, including HBO and STS, in
early lesions is likely to promote healing through multiple
pathways [47]. Treatment using this approach in our PD
population resulted in healing of skin lesions of all cases
despite aggressive presentations.
6.4.4. Bisphosphonate Therapy. Bisphosphonates have an
anti-inﬂammatory action and inhibit osteoprotegerin medi-
ated calciﬁcation [51]. Despite bisphosphonates current
product information contraindication in ESKD, case reports
have document beneﬁt with their use in CUA [52, 53]. Data
to guide safe dosing of bisphosphonate therapy in ESKD
is absent, hence routine use in this population cannot be
recommended.
Due to increasing success with combination therapy of
STS and HBO, our unit reserves bisphosphonate use for
last line therapy. The decision to use bisphosphonate should
include the bone metabolism status; however, the high
mortality in CUA often supervenes a concern of later devel-
opment of adynamic bone disease. The emergence of more
accuratemarkersofboneturnoversuchasC-telopeptideand
N-terminal propeptide of collagen type I may better guide
our use in the future but would require investigation prior to
routine use.
7. Conclusions
The clinical features of CUA in PD patients, the diagnosis,
and possible pathogenetic mechanisms are comparable to
other patient groups with CUA. The risk association of PD
with CUA requires conﬁrmation. Aggressive therapy with
combination STS and HBO, in addition to general measures,
may reduce morbidity and mortality in PD patients with
CUA. Treatment of CUA in PD patients does not diﬀer from
other patient groups except for the intraperitoneal route of
administering STS.
Further prospective studies are needed to clearly identify
theriskfactors,todescribethepathophysiology,inparticular
the diﬀerences from atherosclerosis seen in large arteries,
and to deﬁne and standardize therapy. Adequately powered
randomizedstudieswillbediﬃculttoconductduetothelow
incidence of disease and the high associated mortality caus-
ing hesitancy and ethical consideration in randomization to8 International Journal of Nephrology
a control group. Recently, international CUA registries have
been established to promote knowledge of CUA and progress
therapeutic strategies:
(i) Germany: Calciphylaxie Register, International Col-
laborative Calciphylaxis Network (http://www.calci-
phylaxie.de/),
(ii) USA: Calciphylaxis Registry, KU Medical Cen-
ter, University of Kansas (http://www2.kumc.edu/
calciphylaxisregistry/),
(iii) UK: UK Calciphylaxis Registry, International Collab-
orative Calciphylaxis Network (http://www.calciphy-
laxis.org.uk/).
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